Cingulate

Cingulate FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Cingulate (CING) as of Nov 11, 2026 is 77.54 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 112.70 % — a change of -31.20% (lower).

FCF Conversion

77.54 %

YoY

-31.20%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Cingulate is 2025 77.54 % . FCF Conversion Rate (FCF/EBITDA) of Cingulate was 2024 112.70 % . It decreases by -31.20% lower compared to the previous year.

The Cingulate FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
91.36 USD
Jan 1, 2020
100.41 USD
Jan 1, 2021
54.31 USD
Jan 1, 2022
89.84 USD
Jan 1, 2023
64.83 USD
Jan 1, 2024
112.70 USD
Jan 1, 2025
77.54 USD
The Cingulate FCF Conversion history
YEARFCF ConversionYoY
77.54 %-31.20%
112.70 %+73.83%
64.83 %-27.83%
89.84 %+65.42%
54.31 %-45.91%
100.41 %+9.91%
91.36 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate Stock analysis

What does Cingulate do? Cingulate Inc is a US-based biopharmaceutical company headquartered in Kansas City, Kansas, that focuses on the development, manufacturing, and commercialization of pharmaceutical products. The firm utilizes its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles designed to improve the lives of patients suffering from commonly diagnosed conditions. The company specifically targets the treatment of attention deficit/hyperactivity disorder (ADHD) through its innovative approach to drug delivery. The firm is currently developing two lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). These drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. By employing this technology, Cingulate Inc aims to provide effective treatment options for ADHD across three core patient segments: children aged 6-12, adolescents aged 13-17, and adults aged 18 and older. Cingulate is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cingulate stock

FCF Conversion Rate (FCF/EBITDA) of Cingulate is 77.54 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Cingulate changed from 112.70 % to 77.54 %, representing a -31.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Cingulate since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Cingulate with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Cingulate

All Key Metrics — Cingulate